Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Medical Genetics Laboratory, |
RCV001421039 | SCV001622767 | pathogenic | Charlevoix-Saguenay spastic ataxia | 2020-03-01 | criteria provided, single submitter | clinical testing | |
Kariminejad - |
RCV001814320 | SCV001755107 | likely pathogenic | Abnormal central motor function | 2021-07-10 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003588739 | SCV004281135 | pathogenic | Spastic paraplegia | 2023-06-22 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Asn1094Lysfs*18) in the SACS gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 3486 amino acid(s) of the SACS protein. This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with SACS-related conditions. ClinVar contains an entry for this variant (Variation ID: 1098922). This variant disrupts a region of the SACS protein in which other variant(s) (p.Asn4549Asp) have been determined to be pathogenic (PMID: 15156359, 21507954). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV001421039 | SCV005055554 | pathogenic | Charlevoix-Saguenay spastic ataxia | 2023-12-19 | criteria provided, single submitter | clinical testing |